86% response rate reported as Imugene holds A$5.245 million cash

Clinical response rates meet a short funding runway

Imugene Limited (ASX:IMU) has produced its strongest azer-cel response figures yet in a small early-stage cohort, while its cash position leaves little room for delay. The company held A$5.245 million at 30 September against quarterly operating cash outflow of A$7.495 million, translating to an estimated 0.70 quarters of funding under the Appendix 4C calculation.

The contrast is sharp. In Cohort 3, which combines azer-cel with a BTK inhibitor in patients whose B-cell cancers had progressed on previous BTK inhibitor treatment, six of seven evaluable patients had responded as at 19 October. That represented an 86% overall response rate, comprising three complete responses and three partial responses across follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukaemia and Richter’s transformation. The cohort’s early progress builds on the BTKi cohort responses reported during July.

Early azer-cel data remains limited by follow-up

Imugene also reported an 81% overall response rate in its CAR T-naive Cohort 2, with 22 of 27 evaluable patients responding. Cohort 1, covering patients with diffuse large B-cell lymphoma whose disease had relapsed after or failed to respond to earlier CAR T treatment, had a 68% response rate among 22 evaluable patients as at 5 October.

Those figures are encouraging but remain preliminary. Most responses in Cohort 3 were assessed at Day 28, and the company says further follow-up is required to establish durability and assess performance in larger patient groups. The response counts also include several disclosures made after the September quarter, so the headline clinical data is not a pure quarter-end snapshot.

Placement buys time while further funding is considered

Imugene raised A$11.12 million before costs through a two-tranche placement of about 117.1 million shares at A$0.095 each. The funding included participation from an international commercial-stage biopharmaceutical company, which represented about 14% of the total placement, and is earmarked for azer-cel development in Cohorts 2 and 3 and regulatory planning. The raise had previously been reported as the A$11.12 million placement.

Even after the capital injection, the cash calculation remains tight because Imugene spent A$7.495 million on operations during the quarter. Research and development accounted for A$4.313 million, while staff costs fell 51% to A$1.905 million as headcount declined. The company expects an approximately A$2.1 million R&D tax incentive refund in the December quarter and says it is assessing equity financing and non-dilutive sources, but no subsequent financing is disclosed in this report.

Convertible notes add dilution and repayment pressure

Imugene also reshaped A$2.1 million of CVI Investments notes into senior, unsecured, zero-coupon notes maturing in January 2030. The replacement TAR notes have an initial conversion price of A$0.0664, quarterly reset provisions and a floor of A$0.0398. Half of the TAR notes had been redeemed through the issue of shares by quarter end, while CVI received 25.3 million unlisted warrants exercisable at A$0.0664 until August 2031.

The company’s financing facilities were fully drawn at quarter end, with A$10.525 million of convertible notes outstanding and no unused facilities available. That leaves the next funding decision competing with clinical momentum: Imugene must continue generating trial data while managing note repayments, potential share issuance and a cash balance that is expected to remain under pressure.

Leadership transition arrives during clinical acceleration

Leslie Chong stepped down as chief executive and managing director after nearly 11 years, with senior leaders reporting to Executive Chairman Paul Hopper until a new chief executive commences. After quarter end, John Le Gall, formerly Vice President and Head of Clinical Development at Allogene Therapeutics, was appointed chief medical officer. John Byon left that role by mutual agreement and will continue as a consultant; Imugene said the role was reshaped to match its current clinical scale and cost base and that no interruption to the azer-cel programme was anticipated.